Acacia Pharma markets FDA‑approved hospital‑grade injectables for peri‑operative care, including Barhemsys® (IV amisulpride), a selective dopamine D₂/D₃ antagonist for postoperative nausea and vomiting, and Byfavo® (IV remimazolam), an ultra‑short‑acting benzodiazepine for procedural sedation up to 30 minutes. The company is also advancing APD403, a dual‑route amisulpride formulation targeting acute and delayed chemotherapy‑induced nausea and vomiting. Its direct U.S.

Adcendo ApS is developing first-in-class antibody-drug conjugates (ADCs) targeting specific surface antigens in underserved cancers, addressing the high unmet medical need for effective treatments in these malignancies. Their pipeline includes novel ADCs designed to deliver cytotoxic agents directly to cancer cells, enhancing therapeutic efficacy while minimizing damage to healthy tissue.

Alleviant Medical develops a no-implant shunt therapy designed to alleviate the clinical and economic burden of heart failure. The Alleviant System, which has received Breakthrough Device Designation from the U.S. FDA, aims to improve patient outcomes and reduce healthcare costs associated with heart failure management.

AM Pharma is developing ilofotase alfa, a proprietary recombinant human alkaline phosphatase, as an enzyme replacement therapy for adult hypophosphatasia (HPP). The subcutaneous treatment restores alkaline phosphatase activity, lowering disease‑related pyridoxal‑5′‑phosphate and inorganic pyrophosphate levels, which improves bone mineralization, muscle function, and pain. Phase 1b data show dose‑dependent normalization of HPP biomarkers and a favorable safety profile, positioning ilofotase alfa for Phase 2 trials to address the unmet need in adult HPP patients.

Chance Pharmaceuticals is a clinical-stage biotechnology company developing inhalation therapies for respiratory and central nervous system diseases using a proprietary virtual reality drug development platform. The company focuses on improving drug formulations and expanding the application of biologics in inhalation treatments to enhance patient quality of life.

DIA provides a decentralized oracle platform that utilizes a rollup architecture to deliver real-time, verifiable data across over 50 blockchain networks, supporting more than 20,000 assets. This technology addresses the need for reliable and transparent data feeds in decentralized applications, enabling developers to integrate accurate price information without relying on third-party sources.

Inari Medical develops specialized medical devices for the interventional treatment of cardiovascular diseases, focusing on thrombectomy and venous interventions. Their technology aims to improve patient outcomes by effectively removing blood clots and restoring blood flow in affected vessels.

This startup develops proprietary technology for large-scale reforestation efforts, aiming to offset carbon emissions and combat climate change. Their platform focuses on accelerating forest replenishment to address global deforestation.

MEDiC utilizes a proprietary CRISPR functional genomics platform combined with 3D tumor models to identify cancer biomarkers and novel drug targets with high precision. This approach addresses the challenge of missed potential biomarkers in current drug development, enhancing the accuracy of patient stratification for oncology treatments.

Nexas AI agents integrate data from multiple sales and marketing platforms to produce actionable insights that enhance sales performance and optimize marketing budgets. This technology enables companies to analyze fragmented data and make informed decisions based on precise performance metrics.

Nx provides a build system optimized for monorepos, featuring plugins for popular frameworks and advanced CI capabilities such as remote caching and task distribution. It addresses the inefficiencies of traditional CI systems by significantly reducing build times and costs, enabling developers to ship products faster and more reliably.

RA UNLIMITED harnesses solar photovoltaic technology to generate clean and affordable electricity for homes, businesses, and communities in the Philippines. The company addresses the reliance on fossil fuels by providing sustainable energy solutions that create jobs and enhance the quality of life for Filipinos.

Re is an on‑chain reinsurance protocol that tokenizes real reinsurance treaties, issuing fully collateralized tokens backed by verified insurance premiums. The platform provides institutional investors and insurers with regulated, transparent access to the $800B+ reinsurance market, delivering 8‑16% annual yields that are largely uncorrelated with traditional assets while maintaining defined risk limits and underwriting discipline.

Tive provides a hardware and software platform that utilizes cellular, GPS, and WiFi technologies to deliver real-time tracking and condition monitoring of shipments, including alerts for temperature, humidity, and shock. This solution addresses the lack of visibility in supply chains, ensuring that valuable shipments arrive on time and in optimal condition.

Tryfi provides a smart dog collar that combines high‑precision GPS tracking with AI‑driven health analytics, delivering real‑time location, activity, and physiological data to the Fi mobile app. Owners receive breed‑specific health insights, step and distance metrics, and instant alerts for abnormal patterns, enabling proactive care and safety monitoring for their pets.

Withings provides a range of clinically validated, connected health devices—including smart scales, hybrid smartwatches, blood pressure monitors, sleep sensors, and a toilet‑integrated urine lab—that automatically sync data to its app. The platform aggregates these metrics into a unified health score and offers AI‑driven insights, cardiologist‑reviewed ECGs, and coaching through the Withings+ subscription, enabling users and healthcare teams to monitor and manage health proactively.